Valvular heart disease, including aortic stenosis, mitral regurgitation, and tricuspid disease, is a growing clinical challenge with an ageing population. Catheter-based interventions including TAVI, MitraClip, and emerging TEER and TMVR procedures are extending treatment eligibility to patients previously considered too high-risk for surgery. Understanding durability, optimal patient selection, and antithrombotic management post-transcatheter procedure are active areas of clinical inquiry.
Loading articles...
